Stable Istotope Labelled Tremelimumab Biosimilar – Anti-CTLA4/CD152 mAb – Research Grade
Size | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Istotope Labelled Tremelimumab Biosimilar - Anti-CTLA4/CD152 mAb - Research Grade |
---|---|
Source | CAS 745013-59-6 |
Species | Homo sapiens |
Expression system | Mammalian cells |
Purity | >95% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue Ice |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Aliases /Synonyms | Ticilimumab, CP-675,CP-675,206,CP-675206 clone 11.2.1 |
Reference | PX-TA1177-SIL |
Related Products | PX-P4361 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG2-kappa |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
General information on Anti-CTLA4/CD152(Homo sapiens) (Tremelimumab) Monoclonal Antibody
Tremelimumab is studied for the treatment of Mesothelioma, Liver Neoplasms, Liver Cancer, Liver Cell Caricinoma, and HepatoCellular Carcinoma.
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.